For the Month of: November 2026 (Report No. 4)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
On November 18, 2026, IceCure
Medical Ltd. (the “Company”) issued a press release titled “IceCure Reports Financial & Operational Results for
the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States,”
a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K.
The press release attached
herewith as Exhibit 99.1 (excluding the seventh paragraph thereof) is incorporated by reference into the Company’s Registration
Statements on Form F-3 (File Nos. 333-297030,
333-290046 and 333-258660)
and Form S-8 (File Nos. 333-298361,
333-270982, 333-264578,
333-262620 and 333-281587),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on
Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Exhibit 99.1
IceCure Reports Financial & Operational Results for the Nine
Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States
CAESAREA, Israel, November 18, 2026 /PRNewswire/ -- IceCure Medical
Ltd. (Nasdaq: ICCM) (“IceCure,” “IceCure Medical” or the “Company”), developer of minimally invasive
cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported its financial and operating
results as of and for the nine months ended September 30, 2026.
Third Quarter 2026 Operational and Clinical Highlights
| ● | 83%
Growth in U.S. Sales: U.S. sales of ProSense® and its cryoprobes doubled
year over year during the first nine months of 2026 compared to the same period in 2025. |
| ● | 26% Year-Over-Year Revenue Growth: Total revenues for the first nine months of 2026 increased to approximately $2.6 million,
compared to $2.1 million in the corresponding period of 2025. |
| ● | Expanded U.S. Commercial Reach: The Company’s commercial presence expanded from 11 states in the third quarter of 2025
to 21 states in the third quarter of 2026. |
| ● | Continued
Progress in the ChoICE Study: The Company’s post-marketing study (the “ChoICE”
Study”) evaluating ProSense® cryoablation for the local treatment of
low-risk breast cancer launched the first clinical sites after Institutional Review Board
(“IRB”) approval at West Cancer Center & Research Institute (the “West
Cancer Center”) in Germantown, TN and Adventist Health Glendale in Glendale, CA. |
| ● | International
Commercial and Regulatory Progress: Received regulatory approval from China’s National
Medical Products Administration to market ProSense® as a Class III medical
device and signed an exclusive distribution agreement for ProSense® cryoablation
systems in the Netherlands. |
“We believe the first nine months of 2026
demonstrate the progress we made in translating our regulatory and clinical achievements into commercial growth, particularly in the
United States. U.S. sales increased 83% year over year, while our commercial reach expanded from 11 to 21 states during the third quarter
of 2026. At the same time, we are building the clinical foundation for broader adoption of ProSense® through the ChoICE
Study. We believe these developments position us to continue driving physician adoption and expanding patient access to ProSense®,”
said Eyal Shamir, Chief Executive Officer of IceCure Medical.
ChoICE Study Moving Forward:
Subsequent to the end of the third quarter of 2026, IceCure announced
additional progress in its ChoICE Study:
| ● | Three clinical sites joined the Company’s study, including Legacy Health in Portland, Oregon. |
| ● | The Company announced the enrollment of the first two patients in the ChoICE Study at two U.S. clinical sites: West Cancer Center
in Tennessee and Adventist Health Glendale in California. |
| ● | The
Company announced the successful completion of the first ProSense® cryoablation
treatment in the ChoICE Study. The first patient was treated at West Cancer Center in Germantown,
Tennessee, by Dr. Richard E. Fine, MD, FACS. |
Additional Third Quarter of 2026 Successes:
| ● | Expanded
U.S. Commercial Team: Strengthened the U.S. sales and marketing organization by adding
dedicated professionals in key territories, including New York, Southern California and the
Midwest, and Florida, as well as additional clinical support personnel to support physician
training and adoption of ProSense®. |
| ● | Participation in Leading Medical Events: Participated in key medical
and industry events, including Aptitude Health’s Targeted Medical Education (“TME”) Take the Lead in Breast Cancer Fall
Summit 2026 in New Orleans, LA and the 2026 European Society of Breast Imaging (“EUSOBI”) Congress in Maastricht, Netherlands,
engaging with leading breast cancer specialists and the broader medical community.
|
| ● | Strengthened Clinical Evidence: Highlighted two new peer-reviewed scientific publications supporting the role of cryoablation
in breast cancer treatment de-escalation, including publications addressing early-stage
breast cancer and axillary lymph node metastases. |
| ● | Professional Recognition of Cryoablation: The Society of Interventional
Oncology (“SIO”) submitted a formal petition to the National Comprehensive Cancer Network (“NCCN”) to include
percutaneous cryoablation as a treatment option in its breast cancer guidelines, potentially broadening the range of treatment options
available to eligible patients. |
Financial Results for the Nine Months Ended September 30, 2026
Total revenues for the nine months ended September 30, 2026 increased
approximately 26% to $2.6 million, compared to $2.1 million for the corresponding period in 2025.
Gross profit for the nine months ended September 30, 2026 increased
approximately 22% to $762,000, compared to $626,000 in the corresponding period of 2025.
Research and development expenses for the nine months ended September
30, 2026 were $6.5 million, compared to $5.1 million in the corresponding period of 2025, primarily reflecting increased expenses related
to the ChoICE Study and other clinical and development activities.
Sales and marketing expenses were $3.6 million for the nine months
ended September 30, 2026, compared to $3.0 million in the corresponding period of 2025, primarily reflecting the continued expansion of
the Company’s U.S. commercial activities.
General and administrative expenses were $3.5 million for the nine
months ended September 30, 2026, compared to $3.3 million in the corresponding period of 2025.
Operating loss for the nine months ended September 30, 2026 was $12.9
million, compared to $10.8 million in the corresponding period of 2025.
Net loss for the nine months ended September 30, 2026, was $12.9 million,
compared to $10.8 million in the corresponding period of 2025.
As of September 30, 2026, the Company’s cash and cash equivalents
totaled approximately $8.2 million, and shareholders’ equity was approximately $8.7 million.
Conference call & webcast info:
Wednesday, November 18, 2026, at 10:00 am EST
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at: https://www.veidan-conferenceing.com/icecure
A recording of the webcast will be available at: https://ir.icecure-medical.com/
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets
advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe
and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer.
The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved
to date including in the U.S., Europe, and Asia.
ProSense® cryoablation became
the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with
biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible
for surgery.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking
statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified
by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,”
“seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or
other comparable terms. For example, the Company is using forward-looking statements when it discusses its belief that the first nine
months of 2026 demonstrate the progress the Company has made in translating its regulatory and clinical achievements into commercial
growth; that the ChoICE Study is building the clinical foundation for broader adoption of ProSense®; that the Company’s
developments position it to continue driving physician adoption and expanding patient access to ProSense®; the continued
expansion of its U.S. commercial footprint, active installed base clinic support personnel and physician adoption; the addition of IRB-approved
U.S. clinical sites for the CHoICE Study to support physician adoption; and the belief that professional recognition of cryoablation
through the petition submitted by the SIO can potentially broaden the range of treatment options available to eligible patients. Historical
results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions
to differ materially from those anticipated in these forward-looking statements include, among others: the Company’s planned level
of revenues and capital expenditures; the Company’s available cash and its ability to obtain additional funding; the Company’s
ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company’s
ability to maintain its relationships with suppliers, distributors and other partners; the Company’s ability to maintain or protect
the validity of its patents and other intellectual property; the Company’s ability to expose and educate medical professionals
about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors
set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with
the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC’s website, www.sec.gov.
The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required
by law.
Investor Relations:
Meir Peleg, CFO
investors@icecure-medical.com
+1-888-902-5716
ICECURE MEDICAL LTD.
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL
POSITION
| | |
As of September 30, 2026 | | |
As of December 31, 2025 | |
| | |
(Unaudited) | | |
| |
| | |
U.S. dollars in thousands | |
| | |
| | |
| |
| ASSETS | |
| | |
| |
| CURRENT ASSETS | |
| | |
| |
| Cash and cash equivalents | |
| 8,220 | | |
| 8,897 | |
| Trade receivables | |
| 391 | | |
| 331 | |
| Inventory | |
| 2,578 | | |
| 2,625 | |
| Prepaid expenses and other receivables | |
| 1,298 | | |
| 752 | |
| Total current assets | |
| 12,487 | | |
| 12,605 | |
| | |
| | | |
| | |
| NON-CURRENT ASSETS | |
| | | |
| | |
| Right-of-use assets | |
| 729 | | |
| 239 | |
| Property and equipment, net | |
| 940 | | |
| 993 | |
| Long-term restricted deposits | |
| 53 | | |
| 51 | |
| Total non-current assets | |
| 1,722 | | |
| 1,283 | |
| TOTAL ASSETS | |
| 14,209 | | |
| 13,888 | |
| | |
| | | |
| | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| | |
| | | |
| | |
| CURRENT LIABILITIES | |
| | | |
| | |
| Trade payables | |
| 1,071 | | |
| 863 | |
| Lease liabilities | |
| 255 | | |
| 204 | |
| Employees and employees related benefits | |
| 3,024 | | |
| 2,659 | |
| Other current liabilities | |
| 633 | | |
| 1,098 | |
| Total current liabilities | |
| 4,983 | | |
| 4,824 | |
| | |
| | | |
| | |
| NON-CURRENT LIABILITIES | |
| | | |
| | |
| Long-term lease liabilities | |
| 452 | | |
| 13 | |
| Total non-current liabilities | |
| 452 | | |
| 13 | |
| | |
| | | |
| | |
| SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| Ordinary shares, No par value; Authorized 2,500,000,000 shares; Issued and outstanding: 5,563,265 shares and 2,437,410 shares as of September 30, 2026 and December 31, 2025, respectively | |
| | | |
| | |
| Additional paid-in capital | |
| 142,205 | | |
| 129,487 | |
| Accumulated deficit | |
| (133,431 | ) | |
| (120,436 | ) |
| Total shareholders’ equity | |
| 8,774 | | |
| 9,051 | |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| 14,209 | | |
| 13,888 | |
ICECURE MEDICAL LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| | |
Nine months ended September 30, | |
| | |
2026 | | |
2025 | |
| | |
U.S. dollars in thousands (except per share data) | |
| Revenues | |
| 2,642 | | |
| 2,100 | |
| Cost of revenues | |
| 1,880 | | |
| 1,474 | |
| Gross profit | |
| 762 | | |
| 626 | |
| Research and development expenses | |
| 6,557 | | |
| 5,137 | |
| Sales and marketing expenses | |
| 3,669 | | |
| 3,061 | |
| General and administrative expenses | |
| 3,527 | | |
| 3,306 | |
| Operating loss | |
| 12,991 | | |
| 10,878 | |
| Finance expenses (income), net | |
| 4 | | |
| (67 | ) |
| | |
| | | |
| | |
| Net loss and comprehensive loss | |
| 12,995 | | |
| 10,811 | |
| Basic and diluted net loss per share | |
| 3.57 | | |
| 5.4 | |
| Weighted average number of shares outstanding used in computing basic and diluted loss per share | |
| 3,637,322 | | |
| 2,018,573 | |
ICECURE MEDICAL LTD.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| | |
Nine months ended September 30, | |
| | |
2026 | | |
2025 | |
| | |
U.S. dollars in thousands | |
| Cash flows from operating activities | |
| | |
| |
| | |
| | |
| |
| Net loss | |
| (12,995 | ) | |
| (10,811 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
| Depreciation | |
| 207 | | |
| 224 | |
| Share-based compensation | |
| 687 | | |
| 1,102 | |
| Exchange rate changes in cash and cash equivalents and long-term restricted deposits | |
| (24 | ) | |
| 118 | |
| Other finance cost | |
| - | | |
| (34 | ) |
| Changes in assets and liabilities: | |
| | | |
| | |
| Decrease (increase) in trade receivables | |
| (60 | ) | |
| 117 | |
| Decrease (increase) in prepaid expenses and other receivables | |
| (546 | ) | |
| 145 | |
| Decrease (increase) in inventory | |
| 47 | | |
| (723 | ) |
| Decrease in right of use assets | |
| 228 | | |
| 251 | |
| Increase (decrease) in trade payables | |
| 208 | | |
| (81 | ) |
| Decrease in lease liabilities | |
| (227 | ) | |
| (212 | ) |
| Increase in employees and employees related liabilities | |
| 365 | | |
| 595 | |
| Decrease in other current liabilities | |
| (465 | ) | |
| (246 | ) |
| Net cash used in operating activities | |
| (12,575 | ) | |
| (9,555 | ) |
| | |
| | | |
| | |
| Cash flows from investing activities | |
| | | |
| | |
| Investment in short-term deposits | |
| - | | |
| (5,000 | ) |
| Purchase of property and equipment | |
| (154 | ) | |
| (31 | ) |
| Net cash used in investing activities | |
| (154 | ) | |
| (5,031 | ) |
| | |
| | | |
| | |
| Cash flows from financing activities: | |
| | | |
| | |
| Proceeds from issuance of ordinary shares, warrants and pre-funded warrants, net of issuance costs | |
| 12,020 | | |
| 12,114 | |
| Proceeds from exercise of warrants and pre-funded warrants | |
| 10 | | |
| - | |
| Net cash provided by financing activities | |
| 12,030 | | |
| 12,114 | |
| | |
| | | |
| | |
| Decrease in cash and cash equivalents | |
| (699 | ) | |
| (2,472 | ) |
| Cash and cash equivalents at beginning of the year | |
| 8,897 | | |
| 7,564 | |
| Effect of exchange rate fluctuations on balances of cash and cash equivalents | |
| 22 | | |
| (121 | ) |
| Cash and cash equivalents at end of period | |
| 8,220 | | |
| 4,971 | |
| | |
| | | |
| | |
| Non-cash activities | |
| | | |
| | |
| Obtaining a right-of-use asset in exchange for a lease liability | |
| 718 | | |
| 41 | |